<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786781</article-id><article-id pub-id-type="doi">10.7759/cureus.76792</article-id><article-categories><subj-group subj-group-type="heading"><subject>Integrative/Complementary Medicine</subject></subj-group></article-categories><title-group><article-title>The Effects of Yoga on Key Adipocytokines in Obesity: A Narrative Review of Leptin and Adiponectin</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Shimizu</surname><given-names>Rinne</given-names></name><xref rid="aff-1" ref-type="aff">1</xref><xref rid="aff-2" ref-type="aff">2</xref><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Hajime</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Amitani</surname><given-names>Marie</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Amitani</surname><given-names>Haruka</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JPN </aff><aff id="aff-2">
<label>2</label>
Kampo Medical Center, Kagoshima University Hospital, Kagoshima, JPN </aff><aff id="aff-3">
<label>3</label>
Department of General Medicine, Ryokusenkai Yonemori Hospital, Kagoshima, JPN </aff><aff id="aff-4">
<label>4</label>
Department of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, JPN </aff><author-notes><corresp id="cor1">
Rinne Shimizu <email>rinn20110430@yahoo.co.jp</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>1</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>1</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>e76792</elocation-id><history><date date-type="accepted"><day>31</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Shimizu et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shimizu et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/314722-the-effects-of-yoga-on-key-adipocytokines-in-obesity-a-narrative-review-of-leptin-and-adiponectin">This article is available from https://www.cureus.com/articles/314722-the-effects-of-yoga-on-key-adipocytokines-in-obesity-a-narrative-review-of-leptin-and-adiponectin</self-uri><abstract><p>Obesity is a global health concern that increases the risk of numerous complications, including type 2 diabetes, hypertension, and cardiovascular diseases. Conventional obesity treatments, such as lifestyle modifications, pharmacotherapy, and surgical interventions, are often insufficient, highlighting the need for more efficient and effective approaches. Yoga, an ancient mind-body practice incorporating physical postures (asanas), breathing exercises (pranayama), and meditation, has emerged as a potential therapeutic intervention for obesity management. This review examines the functions of leptin and adiponectin, two key adipocytokines central to obesity, and evaluates the impact of yoga on these hormones. A literature search was conducted using PubMed, Scopus, and Google Scholar with the keywords "yoga" and "adipocytokine" as of May 5, 2024, resulting in the selection of 12 relevant studies. The majority of studies reviewed demonstrated that yoga significantly decreases leptin levels and increases adiponectin levels. Intensive yoga sessions and combined dietary interventions were found to contribute notably to improvements in these hormonal levels. These findings suggest that yoga may improve the balance between leptin and adiponectin, offering beneficial effects on anti-obesity and chronic inflammation reduction. Yoga, as an economical and non-invasive treatment option, presents a promising approach to managing obesity. Further research is expected to elucidate the underlying mechanisms and explore potential clinical applications.</p></abstract><kwd-group kwd-group-type="author"><kwd>adipocytokines</kwd><kwd>adiponectin</kwd><kwd>chronic inflammation</kwd><kwd>hormonal regulation</kwd><kwd>leptin</kwd><kwd>lifestyle intervention</kwd><kwd>obesity management</kwd><kwd>yoga</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Obesity is a major health problem worldwide. People with obesity often develop serious&#x000a0;health disorders like type 2 diabetes, hypertension, and dyslipidemia&#x000a0;[<xref rid="REF1" ref-type="bibr">1</xref>-<xref rid="REF3" ref-type="bibr">3</xref>]. Obesity increases the risk of malignancy, infections, ischemic heart disease, and pulmonary embolism, contributing to significant morbidity and mortality worldwide [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>The pathophysiology of obesity primarily manifests as excessive visceral fat accumulation due to chronic energy imbalance between intake and expenditure. This visceral adipose tissue functions not merely as an energy storage depot but as an active endocrine organ, secreting numerous bioactive substances called adipocytokines that regulate metabolic and immune responses. Among these adipocytokines, leptin and adiponectin play crucial roles in metabolic regulation. Leptin helps control appetite and energy expenditure through its actions on the hypothalamus. However, in obesity, despite elevated leptin levels, the body often becomes resistant to its effects, leading to disrupted appetite regulation and energy metabolism. In contrast, adiponectin, which has anti-inflammatory properties, is typically decreased in obesity. This reduction in adiponectin levels compromises its protective effects against inflammation and metabolic dysfunction. These adipocytokine disturbances collectively contribute to the development of chronic low-grade inflammation, which in turn causes two major pathophysiological changes: insulin resistance and endothelial dysfunction. These conditions are fundamental mechanisms underlying obesity-related disorders such as type 2 diabetes and cardiovascular disease [<xref rid="REF5" ref-type="bibr">5</xref>].</p><p>Current treatments for obesity mainly focus on lifestyle changes, such as dietary restriction and exercising more. However, these lifestyle changes alone often show limited effectiveness, especially in people with chronic obesity. While additional treatment options exist, such as pharmacological treatments including glucagon-like peptide-1 (GLP-1) receptor agonists and surgical interventions, their use is often limited to specific patients due to high costs, limited accessibility, and potential side effects [<xref rid="REF6" ref-type="bibr">6</xref>]. Therefore, there is a critical need for cost-effective, easily accessible, safe, and effective therapeutic options for obesity management.</p><p>Yoga is an ancient mind-body practice. It combines physical movement, breathing exercises, and meditation, making it a whole-body approach to health [<xref rid="REF7" ref-type="bibr">7</xref>]. Traditionally, yoga aims to harmonize the body, mind, and spirit, promoting overall well-being. As a treatment option, yoga has several advantages: it is generally safe, does not require expensive equipment, and can be adapted for different fitness levels&#x000a0;[<xref rid="REF8" ref-type="bibr">8</xref>].</p><p>This review examines how yoga might affect leptin and adiponectin levels in people with obesity. Previous studies examining yoga's effects on these adipocytokines have several limitations: small sample sizes, inconsistent yoga protocols, and short intervention periods. Despite these limitations, several studies have suggested potential benefits. This review synthesizes available research about the effects of yoga on leptin and adiponectin, examining its potential as a complementary approach to existing obesity treatments, particularly for those who have limited access to conventional treatment options.</p></sec><sec sec-type="review"><title>Review</title><p>Chronic inflammation in obesity and leptin</p><p>Leptin is a hormone derived from the obesity gene discovered through research on the pathogenic gene in genetically obese mice. It is primarily secreted by adipose tissue and exerts potent appetite suppression by binding to and activating the long form of its membrane receptor (LEPR-B), which is prominently expressed in the hypothalamus and other brain regions, influencing food intake and energy expenditure. The leptin receptor Ob-Rb shares high homology with gp130, a signaling molecule for inflammatory cytokines, and is known to be expressed in peripheral tissues such as macrophages&#x000a0;[<xref rid="REF9" ref-type="bibr">9</xref>]. Thus, leptin may also act as an inflammatory cytokine in peripheral tissues. Furthermore, studies have shown that leptin-deficient mice and leptin receptor mutant mice exhibit suppressed thrombus formation and neointimal formation after arterial injury, suggesting that leptin may be involved in post-vascular injury remodeling&#x000a0;[<xref rid="REF10" ref-type="bibr">10</xref>]. In other words, leptin is essential for controlling inflammatory responses and maintaining cardiovascular homeostasis&#x000a0;and is thought to be involved in the increase of inflammation not only in obesity but also in cardiovascular disease and type 2 diabetes&#x000a0;[<xref rid="REF11" ref-type="bibr">11</xref>].</p><p>Leptin resistance</p><p>Leptin levels correlate strongly with body fat, as increased adipocytes trigger a rise in leptin to regulate energy balance&#x000a0;[<xref rid="REF12" ref-type="bibr">12</xref>]. However, many obese individuals develop leptin resistance, where hypothalamic neurons become less sensitive or unresponsive to high leptin levels, leading to increased calorie intake and difficulty maintaining weight loss&#x000a0;[<xref rid="REF13" ref-type="bibr">13</xref>,<xref rid="REF14" ref-type="bibr">14</xref>].</p><p>The primary cause of leptin resistance is impaired leptin transport across the blood-brain barrier (BBB). Studies in high-fat diet-induced obese (DIO) rats have shown reduced BBB permeability to leptin despite elevated plasma leptin concentrations&#x000a0;[<xref rid="REF15" ref-type="bibr">15</xref>].</p><p>The second cause of leptin resistance is impaired leptin signaling in neurons. Obese mice show increased expression levels of suppressor of cytokine signaling 3 (SOCS3), a negative feedback regulator of leptin signaling, which has been shown to induce leptin resistance&#x000a0;[<xref rid="REF16" ref-type="bibr">16</xref>,<xref rid="REF17" ref-type="bibr">17</xref>]. Analysis using protein tyrosine phosphatase 1B (PTP1B) knockout mice has demonstrated that PTP1B is also a negative regulator of leptin signaling and contributes to the development of leptin resistance&#x000a0;[<xref rid="REF18" ref-type="bibr">18</xref>,<xref rid="REF19" ref-type="bibr">19</xref>]. Furthermore, PTPRJ (protein tyrosine phosphatase receptor type J) is co-expressed with leptin receptors in hypothalamic neurons and negatively regulates leptin signaling. PTPRJ-deficient mice exhibit enhanced leptin signaling and reduced food intake, resulting in less weight gain compared to wild-type mice. Diet-induced obesity and leptin administration increase PTPRJ expression in the hypothalamus, and PTPRJ overexpression induces leptin resistance. Thus, PTPRJ induction is implicated in the development of leptin resistance, and PTPRJ inhibition may be a potential strategy for improving obesity&#x000a0;[<xref rid="REF20" ref-type="bibr">20</xref>].</p><p>Another mechanism involves hypothalamic inflammation, endoplasmic reticulum stress, and autophagy defects&#x000a0;[<xref rid="REF21" ref-type="bibr">21</xref>,<xref rid="REF22" ref-type="bibr">22</xref>]. Obese mice show increased endoplasmic reticulum stress&#x000a0;[<xref rid="REF23" ref-type="bibr">23</xref>]. Neuronal treatment with stress-inducing agents like tunicamycin, thapsigargin, and brefeldin A inhibits leptin-induced STAT3 activation, which can be reversed by 4-phenylbutyric acid, a chemical chaperone. This suggests that abnormal protein accumulation from endoplasmic reticulum stress contributes to leptin resistance&#x000a0;[<xref rid="REF24" ref-type="bibr">24</xref>,<xref rid="REF25" ref-type="bibr">25</xref>]. Short-term high-fat feeding promotes microglial infiltration and hypothalamic inflammation. Chronic high-fat feeding exacerbates endoplasmic reticulum and oxidative stress, enhancing IKK&#x003b2;/NF-&#x003ba;B signaling and creating a cycle that worsens leptin resistance through SOCS-3 induction. This signaling is further amplified by endoplasmic reticulum stress. Intracerebroventricular administration of tauroursodeoxycholic acid (TUDCA), a molecular chaperone, suppresses NF-&#x003ba;B signaling under chronic high-fat conditions&#x000a0;[<xref rid="REF26" ref-type="bibr">26</xref>]. Both oxidative and endoplasmic reticulum stress in the hypothalamus impairs autophagy, increasing IKK&#x003b2;/NF-&#x003ba;B signaling&#x000a0;[<xref rid="REF27" ref-type="bibr">27</xref>].</p><p>Medical applications of leptin</p><p>Leptin has been anticipated as a potential obesity treatment, but its clinical application has not become widespread. Current pharmacological and behavioral therapies for obesity induce initial weight loss, but this effect is transient due to leptin resistance&#x000a0;[<xref rid="REF28" ref-type="bibr">28</xref>]. Leptin resistance also reduces the effectiveness of exogenous leptin therapy in obese individuals&#x000a0;[<xref rid="REF29" ref-type="bibr">29</xref>].</p><p>Leptin gene therapy is emerging as a new treatment option. It has improved type 1 and type 2 diabetes and diet-induced obesity in animal models, including ob/ob mice, DIO mice, and insulin-deficient diabetic mice. A single central administration of a recombinant adeno-associated virus vector encoding the leptin gene significantly reduced adiposity and improved metabolic syndrome (MetS) symptoms in various models over an extended period. In contrast, obese patients with hyperleptinemia, with or without type 2 diabetes, did not respond to exogenous r-metHuLeptin&#x000a0;[<xref rid="REF22" ref-type="bibr">22</xref>]. Leptin gene therapy is expected to become an effective treatment option for obesity and diabetes. Nevertheless, several challenges remain in the clinical application of leptin gene therapy. For instance, the development of leptin resistance and impaired transport of leptin across the BBB may limit its therapeutic efficacy. Additionally, considerations regarding the safety of viral vectors, the maintenance of long-term efficacy, and the potential risk of immune responses associated with gene therapy must be addressed. Further research is required to overcome these challenges.</p><p>A 2024 report by Francesca Mainieri et al. suggested that leptin gene therapy could be effective in treating genetic obesity caused by loss-of-function mutations in genes involved in the leptin-melanocortin pathway&#x000a0;[<xref rid="REF30" ref-type="bibr">30</xref>]. These loss-of-function mutations in genes involved in the leptin-melanocortin pathway are considered one of the causes of leptin resistance, and with future advances in genetic analysis, innovative pharmacological treatments for various genetic obesities are anticipated.</p><p>Additionally, the gut-brain axis has been identified as a new mechanism for improving leptin resistance in obesity. The gastrointestinal-brain axis refers to the mechanism through which various signaling molecules secreted by the gastrointestinal tract act via the vagus nerve and circulatory pathways to influence the central nervous system, particularly regions such as the hypothalamus and the dorsal motor nucleus of the vagus nerve, to regulate appetite and energy balance. This axis mediates the effects of gastrointestinal-derived hormones, such as ghrelin, on satiety and feeding behavior&#x000a0;[<xref rid="REF31" ref-type="bibr">31</xref>]. Approaches targeting the gastrointestinal-brain axis, by enhancing leptin sensitivity through signals secreted from the digestive tract, offer promise as adjunctive therapeutic strategies. Various anorexigenic signals secreted from the gastrointestinal tract that act on specific brain regions such as the hypothalamus, including uroguanylin, GLP-1, amylin, and cholecystokinin, may alleviate resistance to leptin's effects by promoting the secretion of appetite-suppressing signals&#x000a0;[<xref rid="REF32" ref-type="bibr">32</xref>]. A 2014 report by Folgueira et al. demonstrated that various anorexigenic signals secreted from the gastrointestinal tract, together with leptin, induced significant weight loss even in DIO&#x000a0;mice, a model of leptin resistance&#x000a0;[<xref rid="REF33" ref-type="bibr">33</xref>]. Further elucidation of the gut-brain axis is expected to become a new option for obesity treatment through leptin resistance. This approach suggests the potential of targeting the gastrointestinal-brain axis as an adjunctive therapeutic modality for addressing leptin resistance.</p><p>Chronic inflammation and adiponectin in obesity</p><p>Adiponectin, despite being specifically secreted by adipocytes, decreases in obesity and visceral fat accumulation&#x000a0;[<xref rid="REF34" ref-type="bibr">34</xref>]. It has been shown to have anti-diabetic, anti-atherosclerotic, and anti-inflammatory properties. In obese and type 2 diabetic mouse models, decreased plasma adiponectin levels lead to insulin resistance and dyslipidemia, but appropriate administration of adiponectin improved these pathological conditions&#x000a0;[<xref rid="REF35" ref-type="bibr">35</xref>]. Furthermore, in patients with type 2 diabetes and coronary artery disease matched for body mass index (BMI), blood adiponectin levels were found to be reduced&#x000a0;[<xref rid="REF36" ref-type="bibr">36</xref>].</p><p>Medical applications of adiponectin</p><p>In 2023, Naomi Asahara et al. reported obtaining an antibody that activates adiponectin receptors similarly to adiponectin itself&#x000a0;(Adiponectin Receptor Activating Monoclonal Antibody: AdipoRaMab).&#x000a0;AdipoRaMab binds to adiponectin receptors (Adiponectin Receptor 1: AdipoR1 and Adiponectin Receptor 2: AdipoR2), promoting the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), which activates pathways involved in glucose uptake and oxidative metabolism, thereby enhancing insulin sensitivity in muscle and liver tissues. Additionally, AdipoRaMab suppresses the expression of inflammation-related factors, such as interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), in the liver while increasing the expression of genes related to energy expenditure. These effects contribute to the amelioration of chronic inflammatory conditions, such as non-alcoholic fatty liver disease (NAFLD), including fatty hepatitis&#x000a0;[<xref rid="REF37" ref-type="bibr">37</xref>]. This discovery suggests the potential for treating chronic diseases caused by reduced adiponectin function, beyond diabetes treatment, and future research developments are anticipated.</p><p>Regulation of adipocytokines through yoga</p><p>Yoga emphasizes lifestyle improvement and increased physical activity. It has been shown to be effective in weight reduction and improving lipid profiles in patients with coronary artery disease, diabetes, and hypertension&#x000a0;[<xref rid="REF6" ref-type="bibr">6</xref>,<xref rid="REF38" ref-type="bibr">38</xref>-<xref rid="REF40" ref-type="bibr">40</xref>]. In this narrative review, a literature search was conducted on May 5, 2024, using the keywords "yoga" and "adipocytokine" in major medical literature databases, including PubMed, Scopus, and Google Scholar. A PRISMA 2020 flow diagram was used to illustrate the study selection process&#x000a0;(Figure <xref rid="FIG1" ref-type="fig">1</xref>).&#x000a0;</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>PRISMA 2020 Flow Diagram</title><p>The flowchart illustrates the selection process of studies included in this narrative review. Initially, 198 records were identified through database searches, and after removing duplicates and screening titles/abstracts, 66 records were assessed for full-text eligibility. Following further screening based on the inclusion/exclusion criteria, a total of 12 studies were included in the qualitative synthesis.</p></caption><graphic xlink:href="cureus-0017-00000076792-i01" position="float"/></fig><p>Initially, a total of 198 records were identified through database searches in PubMed (n=17), Scopus (n=13), and Google Scholar (n=168). After removing duplicates, 180 records remained. These records were screened based on their titles and abstracts, leading to the exclusion of 114 records for the following reasons: studies without yoga interventions (n=72), irrelevant studies (n=35), and studies focused on gynecological conditions (e.g., polycystic ovary syndrome, breast cancer, and pregnancy) (n=7). This screening process resulted in 66 records being assessed for full-text review. Of these 66 full-text articles, 54 were excluded for the following reasons: review articles (n=42), editorials/posters/reports (n=5), observational studies (n=4), a cross-sectional study (n=1), a protocol paper (n=1), and combined interventions with other exercises (n=1). Ultimately, 12 studies [<xref rid="REF41" ref-type="bibr">41</xref>-<xref rid="REF52" ref-type="bibr">52</xref>] were included in the qualitative synthesis for this review&#x000a0;(Table <xref rid="TAB1" ref-type="table">1</xref>).&#x000a0;</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Summary of Studies Examining the Effects of Yoga on Adipokines and Health Parameters</title><p>This table summarizes findings from studies evaluating the effects of yoga interventions on adipokines, including leptin, adiponectin, IL-6, visfatin, and chemerin, as well as associated metabolic health parameters across various populations. The included studies encompass a range of designs, such as randomized controlled trials, quasi-experimental studies, and pre-post-intervention studies. Participant groups included individuals with obesity, MetS, type 2 diabetes, and healthy individuals. Yoga protocols varied in duration, frequency, and integration with dietary modifications. Key findings highlight reductions in leptin levels and increases in adiponectin levels, often accompanied by improvements in metabolic markers such as BMI, blood glucose, and lipid profiles (e.g., cholesterol). In several studies, dietary interventions were employed, further potentiating the effects of yoga on adipokine regulation and overall metabolic health.</p><p>8-OHdG, 8-hydroxy-2'-deoxyguanosine; BMI, body mass index; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IL-6: interleukin-6; LDL, low-density lipoprotein; MetS, metabolic syndrome; NA, not available; PAI-1: plasminogen activator inhibitor-1; SOD, superoxide dismutase; TBARS: thiobarbituric acid reactive substances</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Author/year</td><td rowspan="1" colspan="1">Study design</td><td rowspan="1" colspan="1">Participants/sample size</td><td rowspan="1" colspan="1">Yoga protocol</td><td rowspan="1" colspan="1">Diet change advised</td><td rowspan="1" colspan="1">Adipokines assessed</td><td rowspan="1" colspan="1">Key findings (yoga intervention group&#x0ff09;</td></tr><tr><td rowspan="1" colspan="1">Ritesh N, et al./2015 [<xref rid="REF39" ref-type="bibr">39</xref>]</td><td rowspan="1" colspan="1">Pilot study</td><td rowspan="1" colspan="1">Overweight or obese adults (BMI 23-35 kg/m&#x000b2;)/n=34</td><td rowspan="1" colspan="1">10 days yoga program</td><td rowspan="1" colspan="1">Advised healthy eating patterns</td><td rowspan="1" colspan="1">IL-6, vaspin</td><td rowspan="1" colspan="1">Decrease in IL-6, neopterin, vaspin, body weight, BMI, fasting blood glucose, fasting insulin, HOMA-IR, total cholesterol, triglyceride, BMI, waist and hip circumferences.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Daneshyar, et al./2020 [<xref rid="REF40" ref-type="bibr">40</xref>]</td><td rowspan="1" colspan="1">Quasi-experimental study</td><td rowspan="1" colspan="1">Postmenopausal women/n=33</td><td rowspan="1" colspan="1">30-40 minutes, 3 sessions per week, 8 weeks yoga program,</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Visfatin</td><td rowspan="1" colspan="1">No changes in visfatin, liver enzymes, or body composition.</td></tr><tr><td rowspan="1" colspan="1">Supriya R, et al./2018 [<xref rid="REF41" ref-type="bibr">41</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">MetS and high-normal blood pressure/n=97</td><td rowspan="1" colspan="1">1 hour, 3 times per week for 1 year</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Leptin, adiponectin, chemerin, visfatin</td><td rowspan="1" colspan="1">Decreases in leptin and chemerin. Increase in adiponectin. No change in visfatin, PAI-1.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Telles S, et al./2010 [<xref rid="REF42" ref-type="bibr">42</xref>]</td><td rowspan="1" colspan="1">Single group&#x000a0;pre-post intervention study</td><td rowspan="1" colspan="1">Obese persons/n=47</td><td rowspan="1" colspan="1">5 hours, every day for 6 days</td><td rowspan="1" colspan="1">Low fat, high fiber, vegetarian diet</td><td rowspan="1" colspan="1">Leptin</td><td rowspan="1" colspan="1">Decrease in leptin, total cholesterol, HDL cholesterol, BMI, waist and hip circumferences, fat-free mass.</td></tr><tr><td rowspan="1" colspan="1">Yadav R, et al./2019 [<xref rid="REF43" ref-type="bibr">43</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">WetS/n=260</td><td rowspan="1" colspan="1">12 weeks yoga program</td><td rowspan="1" colspan="1">Advised healthy eating patterns</td><td rowspan="1" colspan="1">Leptin, adiponectin, leptin/adiponectin ratio, IL-6</td><td rowspan="1" colspan="1">Decrease in leptin, leptin/adiponectin ratio, IL-6, TBARS, 8-OHdG. Increase in adiponectin, SOD.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Telles S, et al./2010 [<xref rid="REF44" ref-type="bibr">44</xref>]</td><td rowspan="1" colspan="1">Single-group pre-post interventional study</td><td rowspan="1" colspan="1">Type 2 diabetes/n=31</td><td rowspan="1" colspan="1">60-90 minutes, twice a day</td><td rowspan="1" colspan="1">Plant-based diet (1800 kcal/day)</td><td rowspan="1" colspan="1">Leptin, adiponectin</td><td rowspan="1" colspan="1">Decrease in leptin, fasting blood glucose and cholesterol.</td></tr><tr><td rowspan="1" colspan="1">Arciero PJ, et al./2014 [<xref rid="REF45" ref-type="bibr">45</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">Overweight or obese adults (BMI 25-35 kg/m&#x000b2;)/n=79</td><td rowspan="1" colspan="1">PRISE group (protein + resistance training + intervals + stretching/yoga/pilates + endurance): Stretching/yoga/pilates session once a week</td><td rowspan="1" colspan="1">Whey protein protocol</td><td rowspan="1" colspan="1">Leptin, adiponectin</td><td rowspan="1" colspan="1">Decrease in leptin, HOMA-IR, visceral adipose tissue, body weight and fat mass. Increase in adiponectin.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Farideh Y, et al./2020 [<xref rid="REF46" ref-type="bibr">46</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">Obese or overweight women/n=44</td><td rowspan="1" colspan="1">8 weeks yoga program</td><td rowspan="1" colspan="1">Energy-restricted diet of 300 kcal/day</td><td rowspan="1" colspan="1">Leptin, adiponectin</td><td rowspan="1" colspan="1">Decrease in leptin. Increase in adiponectin.</td></tr><tr><td rowspan="1" colspan="1">Lee JA, et al./2012 [<xref rid="REF47" ref-type="bibr">47</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">Postmenopausal women, body fat &#x02265;36%/n=16</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Adiponectin</td><td rowspan="1" colspan="1">Decrease in total cholesterol, triglyceride, LDL, blood pressure, insulin, glucose, and HOMA-IR, body weight, percentage of body fat, lean body mass, BMI, waist circumference, and visceral fat area. Increase in adiponectin, HDL.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sarvottam K, et al./2013 [<xref rid="REF48" ref-type="bibr">48</xref>]</td><td rowspan="1" colspan="1">Nonrandomized pre-post intervention study</td><td rowspan="1" colspan="1">Overweight and obese men (BMI 26.26&#x000b1;2.42 kg/m<sup>2</sup>)/n=51</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">Adiponectin, IL-6</td><td rowspan="1" colspan="1">Decreases in IL-6,&#x000a0;weight, BMI, and systolic blood pressure. Increase in adiponectin.</td></tr><tr><td rowspan="1" colspan="1">Papp ME, et al./2016 [<xref rid="REF49" ref-type="bibr">49</xref>]</td><td rowspan="1" colspan="1">Randomized controlled trial</td><td rowspan="1" colspan="1">Healthy students/n=44</td><td rowspan="1" colspan="1">60 minutes, once a week for 6 weeks</td><td rowspan="1" colspan="1">Low fat, high fiber, vegetarian diet</td><td rowspan="1" colspan="1">Leptin, adiponectin</td><td rowspan="1" colspan="1">No change in leptin. Increase in adiponectin and ApoA1.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Telles S, et al./2014 [<xref rid="REF50" ref-type="bibr">50</xref>]</td><td rowspan="1" colspan="1">Randomized comparative trial</td><td rowspan="1" colspan="1">BMI &#x02265;25 kg/m<sup>2</sup>/n=68</td><td rowspan="1" colspan="1">45 minutes, twice daily</td><td rowspan="1" colspan="1">Plant-based diet (1650 kcal/day)</td><td rowspan="1" colspan="1">Leptin, adiponectin</td><td rowspan="1" colspan="1">Decrease in cholesterol, LDL, lean mass, body water. Increase in leptin.</td></tr></tbody></table></table-wrap><p>The most frequently studied adipocytokine was adiponectin, assessed in nine studies, followed by leptin, examined in eight studies. Other adipocytokines, including IL-6, vaspin, visfatin, chemerin, and PAI-1, were also evaluated. Additionally, some studies measured neopterin, a biomarker indicative of immune system activation related to glucose and lipid metabolism, as well as oxidative stress markers such as thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG).</p><p>Nine of the studies involved subjects with obesity-related conditions such as overweight, MetS, or type 2 diabetes. Two studies focused on healthy individuals. Of the eight studies examining leptin, six reported a decrease in leptin levels. Among the nine studies investigating adiponectin, seven observed an increase in adiponectin levels. Nine studies showed favorable regulation of either leptin or adiponectin, with six of these studies incorporating dietary guidance. Dietary interventions included advised plant-based diets (1650-1800 kcal/day), vegetarian diets, and whey protein supplementation.</p><p>Reduction of leptin levels through yoga</p><p>In a 2018 study by Supriya R, et al., subjects with MetS&#x000a0;and high-normal blood pressure, with a mean age of 57.6&#x000b1;9.1 years, practiced yoga for one year. As a result, leptin levels decreased by approximately 26.5%, from an average of 22.2 ng/mL to 16.3 ng/mL&#x000a0;[<xref rid="REF43" ref-type="bibr">43</xref>].</p><p>Telles et al. reported in 2010 that obese individuals aged 17-68 years with a BMI &#x02265;30 kg/m&#x000b2; participated in a six-day yoga and dietary modification program. Leptin levels decreased by about 44.2%, from an average of 53.71 ng/mL to 29.95 ng/mL&#x000a0;[<xref rid="REF44" ref-type="bibr">44</xref>].</p><p>Yadav et al. examined&#x000a0;Indian adults aged 20-45 years with MetS. After a 12-week yoga and lifestyle intervention program, leptin levels decreased by approximately 16.4%, from 57.49&#x000b1;18.89 ng/mL to 48.08&#x000b1;16.68 ng/mL. The yoga program included asanas (postures), pranayama (breathing techniques), meditation, and shavasana (relaxation technique), along with individualized lifestyle counseling. The recommended diet included 50-60% carbohydrates, &#x0003c;30% total fat, &#x0003c;10% saturated fat, 10-15% protein, 25-40g/day fiber, and &#x0003c;5g/day salt&#x000a0;[<xref rid="REF45" ref-type="bibr">45</xref>].</p><p>In another 2010 study by Telles et al., patients with uncomplicated type 2 diabetes (mean age 47.8&#x000b1;6.2 years) participated in a six-day yoga and dietary modification program for five hours daily. Leptin levels decreased significantly by about 64.1%, from 20.72&#x000b1;22.55 ng/mL to 7.44&#x000b1;7.38 ng/mL&#x000a0;[<xref rid="REF46" ref-type="bibr">46</xref>].</p><p>Arciero et al. studied&#x000a0;overweight or obese individuals aged 35-65 years with BMI &#x02265;25 kg/m&#x000b2;. After 16 weeks of yoga practice and whey protein intake, leptin levels decreased by approximately 35.2%, from 37.5&#x000b1;15.7 ng/mL to 24.3&#x000b1;10.2 ng/mL&#x000a0;[<xref rid="REF47" ref-type="bibr">47</xref>].</p><p>Yazdanparast et al. reported in 2020 that overweight and obese women aged 30-50 years with BMI &#x02265;25 kg/m&#x000b2; participated in an eight-week yoga and dietary modification program. Leptin levels decreased by about 16.4%, from 57.49 ng/mL to 48.08 ng/mL&#x000a0;[<xref rid="REF48" ref-type="bibr">48</xref>].</p><p>These studies suggest that yoga significantly reduces leptin levels. Notably, Supriya et al. demonstrated sustained leptin reduction over a longer period [<xref rid="REF43" ref-type="bibr">43</xref>], supporting the efficacy of long-term yoga practice in managing MetS and obesity. Conversely,&#x000a0;a short-term intensive intervention by Telles et al.&#x000a0;(five hours daily for six days) in patients with uncomplicated type 2 diabetes showed a remarkable 64.1% decrease [<xref rid="REF46" ref-type="bibr">46</xref>], indicating the potential for powerful effects with intensive, short-term yoga practice. The studies also showed enhanced effects when yoga was combined with dietary modifications or whey protein intake [<xref rid="REF44" ref-type="bibr">44</xref>-<xref rid="REF48" ref-type="bibr">48</xref>].</p><p>Increase in adiponectin levels through yoga</p><p>Supriya et al. found that in individuals with MetS and high-normal blood pressure (mean age 57.6&#x000b1;9.1 years), one year of yoga practice increased adiponectin levels by about 20.1%, from 6.48&#x000b1;1.80 &#x000b5;g/mL to 7.77&#x000b1;2.12 &#x000b5;g/mL [<xref rid="REF43" ref-type="bibr">43</xref>]. Yadav et al. examined&#x000a0;Indian adults with MetS (aged 20-45 years)&#x000a0;and found&#x000a0;a 7% increase in adiponectin levels, from 5.18&#x000b1;1.39 &#x000b5;g/mL to 5.54&#x000b1;2.41 &#x000b5;g/mL, after a 12-week yoga and lifestyle intervention program&#x000a0;[<xref rid="REF45" ref-type="bibr">45</xref>]. Arciero et al. investigated&#x000a0;overweight or obese individuals (aged 35-65 years, BMI &#x02265;25 kg/m&#x000b2;)&#x000a0;and found&#x000a0;a 22.9% increase in adiponectin levels, from 18.8&#x000b1;1.90 &#x000b5;g/mL to 23.1&#x000b1;3.10 &#x000b5;g/mL, after 16 weeks of yoga practice and whey protein intake [<xref rid="REF47" ref-type="bibr">47</xref>]. Farideh et al. evaluated&#x000a0;overweight and obese women (aged 30-50 years, BMI &#x02265;25 kg/m&#x000b2;)&#x000a0;and observed&#x000a0;a 12.0% increase in adiponectin levels, from 8.35&#x000b1;2.85 &#x003bc;g/mL to 9.35&#x000b1;3.30 &#x003bc;g/mL, after an eight-week yoga and dietary modification program [<xref rid="REF48" ref-type="bibr">48</xref>]. Lee et al. investigated&#x000a0;postmenopausal obese women (mean age 54.5&#x000b1;2.75 years) with body fat percentage &#x02265;36%&#x000a0;and found&#x000a0;an increase in adiponectin levels by approximately 16.5%, from 6.60&#x000b1;2.08 &#x000b5;g/mL to 7.68&#x000b1;2.420 &#x000b5;g/mL&#x000a0;[<xref rid="REF49" ref-type="bibr">49</xref>]. Sarvottam et al. studied&#x000a0;overweight or obese men (mean age: 39&#x000b1;12.2 years, BMI: 23-35 kg/m&#x000b2;) in a 10-day program of two-hour daily yoga sessions with dietary modifications [<xref rid="REF50" ref-type="bibr">50</xref>]. Adiponectin levels increased by about 26.5%, from 4.95&#x000b1;1.39 &#x000b5;g/mL to 6.26&#x000b1;2.41 &#x000b5;g/mL. The yoga program included asanas, pranayama, group discussions, lectures, and individual counseling. A predominantly plant-based diet was recommended.&#x000a0;Papp et al. studied&#x000a0;healthy students (aged 20-39 years)&#x000a0;and found&#x000a0;a 16.4% increase in adiponectin levels, from 8.32&#x000b1;3.32 &#x000b5;g/mL to 9.68&#x000b1;3.83 &#x000b5;g/mL, after six weeks of 60-minute weekly yoga sessions including asanas, pranayama, and meditation&#x000a0;[<xref rid="REF51" ref-type="bibr">51</xref>].</p><p>These studies demonstrate that yoga significantly increases adiponectin levels.&#x000a0;Supriya et al. demonstrated&#x000a0;a substantial 20.1% increase in adiponectin, suggesting the effectiveness of long-term yoga practice in managing MetS and high normal blood pressure [<xref rid="REF43" ref-type="bibr">43</xref>].&#x000a0;Sarvottam et al. reported&#x000a0;a notable 26.5% increase in adiponectin&#x000a0;among overweight and obese men over just 10 days&#x000a0;[<xref rid="REF51" ref-type="bibr">51</xref>]. The high improvement rate in this short-term study may be attributed to the intensive daily two-hour yoga sessions combined with psychosocial support through group discussions, lectures, and individual counseling. The studies also indicated enhanced effects when yoga was combined with dietary modifications or whey protein intake [<xref rid="REF46" ref-type="bibr">46</xref>-<xref rid="REF48" ref-type="bibr">48</xref>].</p><p>Other outcome</p><p>One study reported an increase in leptin in the yoga practice group, contrary to the general trend&#x000a0;[<xref rid="REF52" ref-type="bibr">52</xref>].&#x000a0;Telles et al. conducted a&#x000a0;randomized comparative trial on overweight and obese individuals (BMI &#x02265;25 kg/m&#x000b2;, n=68),&#x000a0;and found&#x000a0;a 26.8% increase in leptin levels, from 12.3&#x000b1;3.2 ng/mL to 15.6&#x000b1;4.1 ng/mL. The yoga protocol consisted of 45-minute sessions practiced twice daily, combined with a plant-based diet (1650 kcal/day). Additionally, the study found reductions in cholesterol, LDL, lean mass, and body water. These inconsistencies underscore the need for further research in this area.</p><p>Discussion</p><p>Based on the findings from these studies, yoga has been demonstrated to reduce leptin levels while increasing adiponectin levels. A decrease in leptin reduces leptin resistance, facilitating its transport across the BBB and enhancing neural signaling. This, in turn, results in greater appetite suppression and modulation of inflammation and immune responses within the hypothalamus. Conversely, an increase in adiponectin levels enhances adiponectin receptor activity, promoting anti-diabetic, anti-atherosclerotic, and anti-inflammatory effects throughout the body. These findings suggest that yoga may confer potential anti-obesity effects and ameliorate obesity-related chronic inflammation through the regulation of adipokines (Figure <xref rid="FIG2" ref-type="fig">2</xref>).</p><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title> Yoga's Impact on Metabolic Regulation: Leptin and Adiponectin Pathways</title><p>This diagram illustrates the effects of yoga practice on leptin and adiponectin, two key adipokines involved in metabolic regulation. Yoga is shown to decrease leptin levels while increasing adiponectin levels. Reduced leptin leads to decreased leptin resistance, enhancing its passage through the BBB and neural signaling. This results in increased appetite suppression and modulation of inflammation and immune responses in the hypothalamus. Conversely, increased adiponectin levels enhance adiponectin receptor activity, promoting anti-diabetic, anti-atherosclerotic, and anti-inflammatory effects throughout the body. Arrows indicate the direction of change (&#x02191; increase, &#x02193; decrease) in response to yoga practice.</p><p>BBB,&#x000a0;blood-brain barrier</p></caption><graphic xlink:href="cureus-0017-00000076792-i02" position="float"/></fig></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This review demonstrates that yoga can effectively regulate adipocytokines such as leptin and adiponectin, suggesting potential anti-obesity effects and improvement in obesity-related chronic inflammation. Notably, adipocytokine regulation appeared to be particularly beneficial when yoga was combined with dietary interventions, when practiced intensively for two or more hours daily, or when supplemented with psychosocial support such as group discussions, lectures, and individual counseling. Illustrates the effects of yoga on leptin and adiponectin signaling pathways, depicting how yoga practice can decrease leptin levels while increasing adiponectin levels, leading to improved metabolic regulation. However, there was considerable variation in the duration and style of yoga interventions across studies. Recent years have seen growing interest in the development of anti-obesity drugs targeting leptin and adiponectin. In this context, yoga emerges as a cost-effective and non-invasive intervention that could prove highly beneficial. As research in this field continues to accumulate, we can expect a clearer understanding of yoga's role in regulating adipocytokines and its potential as a complementary approach to managing obesity and related metabolic disorders.</p></sec></body><back><ack><p>This work was supported by the Supporting Program for Young Researchers and Regional Activation at Kagoshima University. We sincerely thank Dr. Motohiro Shimizu for his valuable support and guidance during the preparation of this manuscript.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Rinne Shimizu, Hajime Suzuki, Marie Amitani, Haruka Amitani</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Rinne Shimizu, Hajime Suzuki, Marie Amitani, Haruka Amitani</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Rinne Shimizu, Hajime Suzuki, Marie Amitani, Haruka Amitani</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Rinne Shimizu, Hajime Suzuki, Marie Amitani, Haruka Amitani</p><p><bold>Supervision:</bold>&#x000a0; Rinne Shimizu, Hajime Suzuki, Marie Amitani, Haruka Amitani</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>The disease burden associated with overweight and obesity</article-title><source>J Am Med Assoc</source><person-group>
<name><surname>Must</surname><given-names>A</given-names></name>
<name><surname>Spadano</surname><given-names>J</given-names></name>
<name><surname>Coakley</surname><given-names>EH</given-names></name>
<name><surname>Field</surname><given-names>AE</given-names></name>
<name><surname>Colditz</surname><given-names>G</given-names></name>
<name><surname>Dietz</surname><given-names>WH</given-names></name>
</person-group><fpage>1523</fpage><lpage>1529</lpage><volume>282</volume><year>1999</year></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies</article-title><source>Lancet</source><person-group>
<name><surname>Whitlock</surname><given-names>G</given-names></name>
<name><surname>Lewington</surname><given-names>S</given-names></name>
<name><surname>Sherliker</surname><given-names>P</given-names></name>
<etal/>
</person-group><fpage>1083</fpage><lpage>1096</lpage><volume>373</volume><year>2009</year><pub-id pub-id-type="pmid">19299006</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis</article-title><source>BMC Public Health</source><person-group>
<name><surname>Guh</surname><given-names>DP</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Bansback</surname><given-names>N</given-names></name>
<name><surname>Amarsi</surname><given-names>Z</given-names></name>
<name><surname>Birmingham</surname><given-names>CL</given-names></name>
<name><surname>Anis</surname><given-names>AH</given-names></name>
</person-group><fpage>88</fpage><volume>9</volume><year>2009</year><pub-id pub-id-type="pmid">19320986</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Evaluating the cause of death in obese individuals: a ten-year medical autopsy study</article-title><source>J Obes</source><person-group>
<name><surname>Saab</surname><given-names>J</given-names></name>
<name><surname>Salvatore</surname><given-names>SP</given-names></name>
</person-group><fpage>695374</fpage><volume>2015</volume><year>2015</year><pub-id pub-id-type="pmid">25653872</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Once-weekly semaglutide in adults with overweight or obesity</article-title><source>N Engl J Med</source><person-group>
<name><surname>Wilding</surname><given-names>JP</given-names></name>
<name><surname>Batterham</surname><given-names>RL</given-names></name>
<name><surname>Calanna</surname><given-names>S</given-names></name>
<etal/>
</person-group><fpage>989</fpage><lpage>1002</lpage><volume>384</volume><year>2021</year><pub-id pub-id-type="pmid">33567185</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Obesity-related inflammation &#x00026; cardiovascular disease: efficacy of a yoga-based lifestyle intervention</article-title><source>Indian J Med Res</source><person-group>
<name><surname>Sarvottam</surname><given-names>K</given-names></name>
<name><surname>Yadav</surname><given-names>RK</given-names></name>
</person-group><fpage>822</fpage><lpage>834</lpage><volume>139</volume><year>2014</year><uri xlink:href="https://imsear.searo.who.int/items/f8750f71-06e3-4d2f-b4b1-36a95301aec5/full">https://imsear.searo.who.int/items/f8750f71-06e3-4d2f-b4b1-36a95301aec5/full</uri><pub-id pub-id-type="pmid">25109716</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Clinical applications of yoga for the pediatric population: a systematic review</article-title><source>Acad Pediatr</source><person-group>
<name><surname>Birdee</surname><given-names>GS</given-names></name>
<name><surname>Yeh</surname><given-names>GY</given-names></name>
<name><surname>Wayne</surname><given-names>PM</given-names></name>
<name><surname>Phillips</surname><given-names>RS</given-names></name>
<name><surname>Davis</surname><given-names>RB</given-names></name>
<name><surname>Gardiner</surname><given-names>P</given-names></name>
</person-group><fpage>212</fpage><lpage>220</lpage><volume>9</volume><year>2009</year><pub-id pub-id-type="pmid">19608122</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Yogic practices on oxidative stress and of antioxidant level: a systematic review of randomized controlled trials</article-title><source>J Complement Integr Med</source><person-group>
<name><surname>Pal</surname><given-names>R</given-names></name>
<name><surname>Gupta</surname><given-names>N</given-names></name>
</person-group><volume>16</volume><year>2017</year></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues</article-title><source>Proc Natl Acad Sci</source><person-group>
<name><surname>Fei</surname><given-names>H</given-names></name>
<name><surname>Okano</surname><given-names>HJ</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
<name><surname>Lee</surname><given-names>GH</given-names></name>
<name><surname>Zhao</surname><given-names>C</given-names></name>
<name><surname>Darnell</surname><given-names>R</given-names></name>
<name><surname>Friedman</surname><given-names>JM</given-names></name>
</person-group><fpage>7001</fpage><lpage>7005</lpage><volume>94</volume><year>1997</year><pub-id pub-id-type="pmid">9192681</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice</article-title><source>Arterioscler Thromb Vasc Biol</source><person-group>
<name><surname>Stephenson</surname><given-names>K</given-names></name>
<name><surname>Tunstead</surname><given-names>J</given-names></name>
<name><surname>Tsai</surname><given-names>A</given-names></name>
<name><surname>Gordon</surname><given-names>R</given-names></name>
<name><surname>Henderson</surname><given-names>S</given-names></name>
<name><surname>Dansky</surname><given-names>HM</given-names></name>
</person-group><fpage>2027</fpage><lpage>2033</lpage><volume>23</volume><year>2003</year><pub-id pub-id-type="pmid">14500292</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Role of leptin in obesity, cardiovascular disease, and type 2 diabetes</article-title><source>Int J Mol Sci</source><person-group>
<name><surname>Vilari&#x000f1;o-Garc&#x000ed;a</surname><given-names>T</given-names></name>
<name><surname>Polonio-Gonz&#x000e1;lez</surname><given-names>ML</given-names></name>
<name><surname>P&#x000e9;rez-P&#x000e9;rez</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>2338</fpage><volume>25</volume><year>2024</year><pub-id pub-id-type="pmid">38397015</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Adipose tissue, adipokines, and inflammation</article-title><source>J Allergy Clin Immunol</source><person-group>
<name><surname>Fantuzzi</surname><given-names>G</given-names></name>
</person-group><fpage>911</fpage><lpage>919</lpage><volume>115</volume><year>2005</year><pub-id pub-id-type="pmid">15867843</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Adipose tissue leptin production and plasma leptin kinetics in humans</article-title><source>Diabetes</source><person-group>
<name><surname>Klein</surname><given-names>S</given-names></name>
<name><surname>Coppack</surname><given-names>SW</given-names></name>
<name><surname>Mohamed-Ali</surname><given-names>V</given-names></name>
<name><surname>Landt</surname><given-names>M</given-names></name>
</person-group><fpage>984</fpage><lpage>987</lpage><volume>45</volume><year>1996</year><pub-id pub-id-type="pmid">8666153</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Adipokines in health and disease</article-title><source>Trends Pharmacol Sci</source><person-group>
<name><surname>Fasshauer</surname><given-names>M</given-names></name>
<name><surname>Bl&#x000fc;her</surname><given-names>M</given-names></name>
</person-group><fpage>461</fpage><lpage>470</lpage><volume>36</volume><year>2015</year><pub-id pub-id-type="pmid">26022934</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats</article-title><source>Diabetes</source><person-group>
<name><surname>Burguera</surname><given-names>B</given-names></name>
<name><surname>Couce</surname><given-names>ME</given-names></name>
<name><surname>Curran</surname><given-names>GL</given-names></name>
<name><surname>Jensen</surname><given-names>MD</given-names></name>
<name><surname>Lloyd</surname><given-names>RV</given-names></name>
<name><surname>Cleary</surname><given-names>MP</given-names></name>
<name><surname>Poduslo</surname><given-names>JF</given-names></name>
</person-group><fpage>1219</fpage><lpage>1223</lpage><volume>49</volume><year>2000</year><pub-id pub-id-type="pmid">10909981</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Identification of SOCS-3 as a potential mediator of central leptin resistance</article-title><source>Mol Cell</source><person-group>
<name><surname>Bjorbaek</surname><given-names>C</given-names></name>
<name><surname>Elmquist</surname><given-names>JK</given-names></name>
<name><surname>Frantz</surname><given-names>JD</given-names></name>
<etal/>
</person-group><fpage>619</fpage><lpage>625</lpage><volume>1</volume><year>1998</year><pub-id pub-id-type="pmid">9660946</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>The role of SOCS-3 in leptin signaling and leptin resistance</article-title><source>J Biol Chem</source><person-group>
<name><surname>Bj&#x000f8;rbaek</surname><given-names>C</given-names></name>
<name><surname>El-Haschimi</surname><given-names>K</given-names></name>
<name><surname>Frantz</surname><given-names>JD</given-names></name>
<name><surname>Flier</surname><given-names>JS</given-names></name>
</person-group><fpage>30059</fpage><lpage>30065</lpage><volume>274</volume><year>1999</year><pub-id pub-id-type="pmid">10514492</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B</article-title><source>Dev Cell</source><person-group>
<name><surname>Cheng</surname><given-names>A</given-names></name>
<name><surname>Uetani</surname><given-names>N</given-names></name>
<name><surname>Simoncic</surname><given-names>PD</given-names></name>
<etal/>
</person-group><fpage>497</fpage><lpage>503</lpage><volume>2</volume><year>2002</year><pub-id pub-id-type="pmid">11970899</pub-id>
</element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>PTP1B regulates leptin signal transduction in vivo</article-title><source>Dev Cell</source><person-group>
<name><surname>Zabolotny</surname><given-names>JM</given-names></name>
<name><surname>Bence-Hanulec</surname><given-names>KK</given-names></name>
<name><surname>Stricker-Krongrad</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>489</fpage><lpage>495</lpage><volume>2</volume><year>2002</year><pub-id pub-id-type="pmid">11970898</pub-id>
</element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>PTPRJ inhibits Leptin Signaling, and induction of PTPRJ in the hypothalamus is a cause of the development of leptin resistance</article-title><source>Sci Rep</source><person-group>
<name><surname>Shintani</surname><given-names>T</given-names></name>
<name><surname>Higashi</surname><given-names>S</given-names></name>
<name><surname>Suzuki</surname><given-names>R</given-names></name>
<etal/>
</person-group><fpage>11627</fpage><volume>7</volume><year>2017</year><pub-id pub-id-type="pmid">28912580</pub-id>
</element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?</article-title><source>Intern Emerg Med</source><person-group>
<name><surname>Calabr&#x000f2;</surname><given-names>P</given-names></name>
<name><surname>Golia</surname><given-names>E</given-names></name>
<name><surname>Maddaloni</surname><given-names>V</given-names></name>
<etal/>
</person-group><fpage>25</fpage><lpage>34</lpage><volume>4</volume><year>2009</year><pub-id pub-id-type="pmid">19052701</pub-id>
</element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>The role of leptin in the control of insulin-glucose axis</article-title><source>Front Neurosci</source><person-group>
<name><surname>Amitani</surname><given-names>M</given-names></name>
<name><surname>Asakawa</surname><given-names>A</given-names></name>
<name><surname>Amitani</surname><given-names>H</given-names></name>
<name><surname>Inui</surname><given-names>A</given-names></name>
</person-group><fpage>51</fpage><volume>7</volume><year>2013</year><pub-id pub-id-type="pmid">23579596</pub-id>
</element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes</article-title><source>Science</source><person-group>
<name><surname>Ozcan</surname><given-names>U</given-names></name>
<name><surname>Cao</surname><given-names>Q</given-names></name>
<name><surname>Yilmaz</surname><given-names>E</given-names></name>
<etal/>
</person-group><fpage>457</fpage><lpage>461</lpage><volume>306</volume><year>2004</year><pub-id pub-id-type="pmid">15486293</pub-id>
</element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Possible involvement of endoplasmic reticulum stress in obesity associated with leptin resistance</article-title><source>J Med Invest</source><person-group>
<name><surname>Hosoi</surname><given-names>T</given-names></name>
<name><surname>Ozawa</surname><given-names>K</given-names></name>
</person-group><fpage>296</fpage><lpage>298</lpage><volume>56 Suppl</volume><year>2009</year><pub-id pub-id-type="pmid">20224207</pub-id>
</element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Endoplasmic reticulum stress plays a central role in development of leptin resistance</article-title><source>Cell Metab</source><person-group>
<name><surname>Ozcan</surname><given-names>L</given-names></name>
<name><surname>Ergin</surname><given-names>AS</given-names></name>
<name><surname>Lu</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>35</fpage><lpage>51</lpage><volume>9</volume><year>2009</year><pub-id pub-id-type="pmid">19117545</pub-id>
</element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity</article-title><source>Cell</source><person-group>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>G</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Karin</surname><given-names>M</given-names></name>
<name><surname>Bai</surname><given-names>H</given-names></name>
<name><surname>Cai</surname><given-names>D</given-names></name>
</person-group><fpage>61</fpage><lpage>73</lpage><volume>135</volume><year>2008</year><pub-id pub-id-type="pmid">18854155</pub-id>
</element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Defective hypothalamic autophagy directs the central pathogenesis of obesity via the IkappaB kinase beta (IKKbeta)/NF-kappaB pathway</article-title><source>J Biol Chem</source><person-group>
<name><surname>Meng</surname><given-names>Q</given-names></name>
<name><surname>Cai</surname><given-names>D</given-names></name>
</person-group><fpage>32324</fpage><lpage>32332</lpage><volume>286</volume><year>2011</year><pub-id pub-id-type="pmid">21784844</pub-id>
</element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Obesity</article-title><source>N Engl J Med</source><person-group>
<name><surname>Yanovski</surname><given-names>SZ</given-names></name>
<name><surname>Yanovski</surname><given-names>JA</given-names></name>
</person-group><fpage>591</fpage><lpage>602</lpage><volume>346</volume><year>2002</year><pub-id pub-id-type="pmid">11856799</pub-id>
</element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>Leptin and obesity: role and clinical implication</article-title><source>Front Endocrinol (Lausanne)</source><person-group>
<name><surname>Obradovic</surname><given-names>M</given-names></name>
<name><surname>Sudar-Milovanovic</surname><given-names>E</given-names></name>
<name><surname>Soskic</surname><given-names>S</given-names></name>
<etal/>
</person-group><fpage>585887</fpage><volume>12</volume><year>2021</year><pub-id pub-id-type="pmid">34084149</pub-id>
</element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Rare genetic forms of obesity in childhood and adolescence: a narrative review of the main treatment options with a focus on innovative pharmacological therapies</article-title><source>Eur J Pediatr</source><person-group>
<name><surname>Mainieri</surname><given-names>F</given-names></name>
<name><surname>La Bella</surname><given-names>S</given-names></name>
<name><surname>Rinaldi</surname><given-names>M</given-names></name>
<name><surname>Chiarelli</surname><given-names>F</given-names></name>
</person-group><fpage>1499</fpage><lpage>1508</lpage><volume>183</volume><year>2024</year><pub-id pub-id-type="pmid">38227053</pub-id>
</element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>Gut-brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function</article-title><source>Postgrad Med J</source><person-group>
<name><surname>Arneth</surname><given-names>BM</given-names></name>
</person-group><fpage>446</fpage><lpage>452</lpage><volume>94</volume><year>2018</year><pub-id pub-id-type="pmid">30026389</pub-id>
</element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Novel mechanisms involved in leptin sensitization in obesity</article-title><source>Biochem Pharmacol</source><person-group>
<name><surname>Pena-Leon</surname><given-names>V</given-names></name>
<name><surname>Perez-Lois</surname><given-names>R</given-names></name>
<name><surname>Villalon</surname><given-names>M</given-names></name>
<etal/>
</person-group><fpage>116129</fpage><volume>223</volume><year>2024</year><pub-id pub-id-type="pmid">38490517</pub-id>
</element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>The brain-stomach connection</article-title><source>Front Horm Res</source><person-group>
<name><surname>Folgueira</surname><given-names>C</given-names></name>
<name><surname>Seoane</surname><given-names>LM</given-names></name>
<name><surname>Casanueva</surname><given-names>FF</given-names></name>
</person-group><fpage>83</fpage><lpage>92</lpage><volume>42</volume><year>2014</year><pub-id pub-id-type="pmid">24732927</pub-id>
</element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity</article-title><source>Biochem Biophys Res Commun</source><person-group>
<name><surname>Arita</surname><given-names>Y</given-names></name>
<name><surname>Kihara</surname><given-names>S</given-names></name>
<name><surname>Ouchi</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>79</fpage><lpage>83</lpage><volume>257</volume><year>1999</year><pub-id pub-id-type="pmid">10092513</pub-id>
</element-citation></ref><ref id="REF35"><label>35</label><element-citation publication-type="journal"><article-title>The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity</article-title><source>Nat Med</source><person-group>
<name><surname>Yamauchi</surname><given-names>T</given-names></name>
<name><surname>Kamon</surname><given-names>J</given-names></name>
<name><surname>Waki</surname><given-names>H</given-names></name>
<etal/>
</person-group><fpage>941</fpage><lpage>946</lpage><volume>7</volume><year>2001</year><pub-id pub-id-type="pmid">11479627</pub-id>
</element-citation></ref><ref id="REF36"><label>36</label><element-citation publication-type="journal"><article-title>Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients</article-title><source>Arterioscler Thromb Vasc Biol</source><person-group>
<name><surname>Hotta</surname><given-names>K</given-names></name>
<name><surname>Funahashi</surname><given-names>T</given-names></name>
<name><surname>Arita</surname><given-names>Y</given-names></name>
<etal/>
</person-group><fpage>1595</fpage><lpage>1599</lpage><volume>20</volume><year>2000</year><pub-id pub-id-type="pmid">10845877</pub-id>
</element-citation></ref><ref id="REF37"><label>37</label><element-citation publication-type="journal"><article-title>A monoclonal antibody activating AdipoR for type 2 diabetes and nonalcoholic steatohepatitis</article-title><source>Sci Adv</source><person-group>
<name><surname>Asahara</surname><given-names>N</given-names></name>
<name><surname>Okada-Iwabu</surname><given-names>M</given-names></name>
<name><surname>Iwabu</surname><given-names>M</given-names></name>
<name><surname>Wada</surname><given-names>K</given-names></name>
<name><surname>Oka</surname><given-names>K</given-names></name>
<name><surname>Yamauchi</surname><given-names>T</given-names></name>
<name><surname>Kadowaki</surname><given-names>T</given-names></name>
</person-group><fpage>0</fpage><volume>9</volume><year>2023</year></element-citation></ref><ref id="REF38"><label>38</label><element-citation publication-type="journal"><article-title>A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus</article-title><source>J Altern Complement Med</source><person-group>
<name><surname>Bijlani</surname><given-names>RL</given-names></name>
<name><surname>Vempati</surname><given-names>RP</given-names></name>
<name><surname>Yadav</surname><given-names>RK</given-names></name>
<etal/>
</person-group><fpage>267</fpage><lpage>274</lpage><volume>11</volume><year>2005</year><pub-id pub-id-type="pmid">15865492</pub-id>
</element-citation></ref><ref id="REF39"><label>39</label><element-citation publication-type="journal"><article-title>Therapeutic potential of yoga practices in modifying cardiovascular risk profile in middle aged men and women</article-title><source>J Assoc Physicians India</source><person-group>
<name><surname>Damodaran</surname><given-names>A</given-names></name>
<name><surname>Malathi</surname><given-names>A</given-names></name>
<name><surname>Patil</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>633</fpage><lpage>640</lpage><volume>50</volume><year>2002</year><uri xlink:href="https://imsear.searo.who.int/handle/123456789/91415">https://imsear.searo.who.int/handle/123456789/91415</uri><pub-id pub-id-type="pmid">12186115</pub-id>
</element-citation></ref><ref id="REF40"><label>40</label><element-citation publication-type="journal"><article-title>Lipid profile of coronary risk subjects following yogic lifestyle intervention</article-title><source>Indian Heart J</source><person-group>
<name><surname>Mahajan</surname><given-names>AS</given-names></name>
<name><surname>Reddy</surname><given-names>KS</given-names></name>
<name><surname>Sachdeva</surname><given-names>U</given-names></name>
</person-group><fpage>37</fpage><lpage>40</lpage><volume>51</volume><year>1999</year><uri xlink:href="https://imsear.searo.who.int/handle/123456789/4937">https://imsear.searo.who.int/handle/123456789/4937</uri><pub-id pub-id-type="pmid">10327777</pub-id>
</element-citation></ref><ref id="REF41"><label>41</label><element-citation publication-type="journal"><article-title>Interleukin-6, vitamin D &#x00026; diabetes risk-factors modified by a short-term yoga-based lifestyle intervention in overweight/obese individuals</article-title><source>Indian J Med Res</source><person-group>
<name><surname>Netam</surname><given-names>R</given-names></name>
<name><surname>Yadav</surname><given-names>RK</given-names></name>
<name><surname>Khadgawat</surname><given-names>R</given-names></name>
<name><surname>Sarvottam</surname><given-names>K</given-names></name>
<name><surname>Yadav</surname><given-names>R</given-names></name>
</person-group><fpage>775</fpage><lpage>782</lpage><volume>141</volume><year>2015</year><pub-id pub-id-type="pmid">26205020</pub-id>
</element-citation></ref><ref id="REF42"><label>42</label><element-citation publication-type="journal"><article-title>Effect of yoga with and without elastic band resistance training on visfatin, liver enzymes and body composition in postmenopausal women</article-title><source>Comp Exerc Physiol</source><person-group>
<name><surname>Daneshyar</surname><given-names>F</given-names></name>
<name><surname>Moradi</surname><given-names>F</given-names></name>
<name><surname>Atashak</surname><given-names>S</given-names></name>
</person-group><fpage>347</fpage><lpage>355</lpage><volume>16</volume><year>2020</year></element-citation></ref><ref id="REF43"><label>43</label><element-citation publication-type="journal"><article-title>Yoga training modulates adipokines in adults with high-normal blood pressure and metabolic syndrome</article-title><source>Scand J Med Sci Sports</source><person-group>
<name><surname>Supriya</surname><given-names>R</given-names></name>
<name><surname>Yu</surname><given-names>AP</given-names></name>
<name><surname>Lee</surname><given-names>PH</given-names></name>
<etal/>
</person-group><fpage>1130</fpage><lpage>1138</lpage><volume>28</volume><year>2018</year><pub-id pub-id-type="pmid">29205515</pub-id>
</element-citation></ref><ref id="REF44"><label>44</label><element-citation publication-type="journal"><article-title>Short term health impact of a yoga and diet change program on obesity</article-title><source>Med Sci Monit</source><person-group>
<name><surname>Telles</surname><given-names>S</given-names></name>
<name><surname>Naveen</surname><given-names>VK</given-names></name>
<name><surname>Balkrishna</surname><given-names>A</given-names></name>
<etal/>
</person-group><fpage>35</fpage><lpage>40</lpage><volume>16</volume><year>2010</year><uri xlink:href="https://medscimonit.com/abstract/index/idArt/878317">https://medscimonit.com/abstract/index/idArt/878317</uri></element-citation></ref><ref id="REF45"><label>45</label><element-citation publication-type="journal"><article-title>Comparative efficacy of a 12 week yoga-based lifestyle intervention and dietary intervention on adipokines, inflammation, and oxidative stress in adults with metabolic syndrome: a randomized controlled trial</article-title><source>Transl Behav Med</source><person-group>
<name><surname>Yadav</surname><given-names>R</given-names></name>
<name><surname>Yadav</surname><given-names>RK</given-names></name>
<name><surname>Khadgawat</surname><given-names>R</given-names></name>
<name><surname>Pandey</surname><given-names>RM</given-names></name>
</person-group><fpage>594</fpage><lpage>604</lpage><volume>9</volume><year>2019</year><pub-id pub-id-type="pmid">30020512</pub-id>
</element-citation></ref><ref id="REF46"><label>46</label><element-citation publication-type="journal"><article-title>Serum leptin, cholesterol and blood glucose levels in diabetics following a yoga and diet change program</article-title><source>Med Sci Monit</source><person-group>
<name><surname>Telles</surname><given-names>S</given-names></name>
<name><surname>Naveen</surname><given-names>VK</given-names></name>
<name><surname>Balkrishna</surname><given-names>A</given-names></name>
</person-group><fpage>4</fpage><lpage>5</lpage><volume>16</volume><year>2010</year><uri xlink:href="https://medscimonit.com/abstract/index/idArt/878468">https://medscimonit.com/abstract/index/idArt/878468</uri></element-citation></ref><ref id="REF47"><label>47</label><element-citation publication-type="journal"><article-title>Timed-daily ingestion of whey protein and exercise training reduces visceral adipose tissue mass and improves insulin resistance: the PRISE study</article-title><source>J Appl Physiol (1985)</source><person-group>
<name><surname>Arciero</surname><given-names>PJ</given-names></name>
<name><surname>Baur</surname><given-names>D</given-names></name>
<name><surname>Connelly</surname><given-names>S</given-names></name>
<name><surname>Ormsbee</surname><given-names>MJ</given-names></name>
</person-group><fpage>1</fpage><lpage>10</lpage><volume>117</volume><year>2014</year><pub-id pub-id-type="pmid">24833780</pub-id>
</element-citation></ref><ref id="REF48"><label>48</label><element-citation publication-type="journal"><article-title>Comparing between the effect of energy-restricted diet and yoga on the resting metabolic rate, anthropometric indices, and serum adipokine levels in overweight and obese staff women</article-title><source>J Res Med Sci</source><person-group>
<name><surname>Yazdanparast</surname><given-names>F</given-names></name>
<name><surname>Jafarirad</surname><given-names>S</given-names></name>
<name><surname>Borazjani</surname><given-names>F</given-names></name>
<name><surname>Haghighizadeh</surname><given-names>MH</given-names></name>
<name><surname>Jahanshahi</surname><given-names>A</given-names></name>
</person-group><fpage>37</fpage><volume>25</volume><year>2020</year><pub-id pub-id-type="pmid">32582343</pub-id>
</element-citation></ref><ref id="REF49"><label>49</label><element-citation publication-type="journal"><article-title>Effects of yoga exercise on serum adiponectin and metabolic syndrome factors in obese postmenopausal women</article-title><source>Menopause</source><person-group>
<name><surname>Lee</surname><given-names>JA</given-names></name>
<name><surname>Kim</surname><given-names>JW</given-names></name>
<name><surname>Kim</surname><given-names>DY</given-names></name>
</person-group><fpage>296</fpage><lpage>301</lpage><volume>19</volume><year>2012</year><pub-id pub-id-type="pmid">22089179</pub-id>
</element-citation></ref><ref id="REF50"><label>50</label><element-citation publication-type="journal"><article-title>Adiponectin, interleukin-6, and cardiovascular disease risk factors are modified by a short-term yoga-based lifestyle intervention in overweight and obese men</article-title><source>J Altern Complement Med</source><person-group>
<name><surname>Sarvottam</surname><given-names>K</given-names></name>
<name><surname>Magan</surname><given-names>D</given-names></name>
<name><surname>Yadav</surname><given-names>RK</given-names></name>
<name><surname>Mehta</surname><given-names>N</given-names></name>
<name><surname>Mahapatra</surname><given-names>SC</given-names></name>
</person-group><fpage>397</fpage><lpage>402</lpage><volume>19</volume><year>2013</year><pub-id pub-id-type="pmid">23210469</pub-id>
</element-citation></ref><ref id="REF51"><label>51</label><element-citation publication-type="journal"><article-title>Effects of high-intensity hatha yoga on cardiovascular fitness, adipocytokines, and apolipoproteins in healthy students: a randomized controlled study</article-title><source>J Altern Complement Med</source><person-group>
<name><surname>Papp</surname><given-names>ME</given-names></name>
<name><surname>Lindfors</surname><given-names>P</given-names></name>
<name><surname>Nygren-Bonnier</surname><given-names>M</given-names></name>
<name><surname>Gullstrand</surname><given-names>L</given-names></name>
<name><surname>W&#x000e4;ndell</surname><given-names>PE</given-names></name>
</person-group><fpage>81</fpage><lpage>87</lpage><volume>22</volume><year>2016</year><pub-id pub-id-type="pmid">26565690</pub-id>
</element-citation></ref><ref id="REF52"><label>52</label><element-citation publication-type="journal"><article-title>A comparative controlled trial comparing the effects of yoga and walking for overweight and obese adults</article-title><source>Med Sci Monit</source><person-group>
<name><surname>Telles</surname><given-names>S</given-names></name>
<name><surname>Sharma</surname><given-names>SK</given-names></name>
<name><surname>Yadav</surname><given-names>A</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Balkrishna</surname><given-names>A</given-names></name>
</person-group><fpage>894</fpage><lpage>904</lpage><volume>20</volume><year>2014</year><pub-id pub-id-type="pmid">24878827</pub-id>
</element-citation></ref></ref-list></back></article>